$PHAT
Phathom Pharmaceuticals, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022002536 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.25M $19.49M $62.74M
YoY Change 55.74% 80.61% 127.99%
% of Gross Profit
Research & Development $17.66M $13.55M $72.34M
YoY Change -14.19% -67.47% -26.3%
% of Gross Profit
Depreciation & Amortization $128.0K $135.0K $521.0K
YoY Change 2.4% 35.0% 61.3%
% of Gross Profit
Operating Expenses $37.91M $33.04M $135.1M
YoY Change 12.87% -36.99% 7.49%
Operating Profit -$37.91M -$135.1M
YoY Change 12.87% 7.49%
Interest Expense $2.759M -$2.769M $6.788M
YoY Change 116.9% 116.33% 48.18%
% of Operating Profit
Other Income/Expense, Net -$2.759M -$17.00K -$8.803M
YoY Change 119.14% -98.67% 158.68%
Pretax Income -$40.67M -$35.83M -$143.9M
YoY Change 16.72% -33.31% 11.48%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$40.67M -$35.83M -$143.9M
YoY Change 16.71% -33.31% 11.48%
Net Earnings / Revenue
Basic Earnings Per Share -$1.07 -$3.89
Diluted Earnings Per Share -$1.069M -$1.123M -$4.716M
COMMON SHARES
Basic Shares Outstanding 31.71M 37.00M
Diluted Shares Outstanding 38.04M 37.00M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.1M $183.3M $183.3M
YoY Change -41.98% -36.26% -36.26%
Cash & Equivalents $138.1M $183.3M $183.3M
Short-Term Investments
Other Short-Term Assets $7.651M $3.267M $3.267M
YoY Change 59.4% -16.23% -16.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $145.7M $186.5M $186.5M
YoY Change -39.97% -35.98% -35.99%
LONG-TERM ASSETS
Property, Plant & Equipment $708.0K $650.0K $2.564M
YoY Change -77.88% -34.08% -24.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $805.0K $341.0K $341.0K
YoY Change 101.25% -11.2% -14.75%
Total Long-Term Assets $3.308M $2.905M $2.905M
YoY Change -8.11% -22.39% -21.49%
TOTAL ASSETS
Total Short-Term Assets $145.7M $186.5M $186.5M
Total Long-Term Assets $3.308M $2.905M $2.905M
Total Assets $149.0M $189.4M $189.4M
YoY Change -39.51% -35.81% -35.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.858M $5.150M $5.150M
YoY Change -73.78% -69.31% -69.35%
Accrued Expenses $7.565M $11.41M $13.77M
YoY Change -58.43% 7.53% -56.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Short-Term Liabilities $11.39M $18.92M $18.92M
YoY Change -72.07% -65.92% -65.91%
LONG-TERM LIABILITIES
Long-Term Debt $91.04M $89.67M $89.67M
YoY Change 155.72% 126.25% 126.44%
Other Long-Term Liabilities $7.500M $7.500M $8.683M
YoY Change 33.93% 81.82% 52.33%
Total Long-Term Liabilities $98.54M $97.17M $98.35M
YoY Change 139.17% 122.06% 117.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.39M $18.92M $18.92M
Total Long-Term Liabilities $98.54M $97.17M $98.35M
Total Liabilities $111.0M $117.3M $117.3M
YoY Change 35.38% 16.3% 16.34%
SHAREHOLDERS EQUITY
Retained Earnings -$570.0M -$529.4M
YoY Change 37.32%
Common Stock $608.1M $601.5M
YoY Change 3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.04M $72.16M $72.16M
YoY Change
Total Liabilities & Shareholders Equity $149.0M $189.4M $189.4M
YoY Change -39.51% -35.81% -35.81%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$40.67M -$35.83M -$143.9M
YoY Change 16.71% -33.31% 11.48%
Depreciation, Depletion And Amortization $128.0K $135.0K $521.0K
YoY Change 2.4% 35.0% 61.3%
Cash From Operating Activities -$45.10M -$41.42M -$148.6M
YoY Change -9.37% 46.89% 113.26%
INVESTING ACTIVITIES
Capital Expenditures $67.00K -$100.0K $328.0K
YoY Change -60.36% -16.67% -68.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$67.00K -$100.0K -$328.0K
YoY Change -60.36% -16.67% -68.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $54.13M
YoY Change
Cash From Financing Activities 0.000 163.0K 44.71M
YoY Change -100.0% -99.82% -60.94%
NET CHANGE
Cash From Operating Activities -45.10M -41.42M -148.6M
Cash From Investing Activities -67.00K -100.0K -328.0K
Cash From Financing Activities 0.000 163.0K 44.71M
Net Change In Cash -45.17M -41.36M -104.2M
YoY Change -8.79% -167.65% -338.36%
FREE CASH FLOW
Cash From Operating Activities -$45.10M -$41.42M -$148.6M
Capital Expenditures $67.00K -$100.0K $328.0K
Free Cash Flow -$45.17M -$41.32M -$148.9M
YoY Change -9.54% 47.16% 110.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001783183
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39094
CY2021 dei Entity Registrant Name
EntityRegistrantName
PHATHOM PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4151574
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2021 dei City Area Code
CityAreaCode
877
CY2021 dei Local Phone Number
LocalPhoneNumber
742-8466
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
PHAT
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
684200000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31712742
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183259000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
287496000
CY2021Q4 phat Prepaid Expenses And Other Assets Related Parties Current
PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
CY2020Q4 phat Prepaid Expenses And Other Assets Related Parties Current
PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
82000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3267000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3872000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
186526000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
291368000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
986000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2373000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
341000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
384000
CY2021Q4 us-gaap Assets
Assets
189431000
CY2020Q4 us-gaap Assets
Assets
295111000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1343000
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
173000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5150000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16782000
CY2021Q4 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
1402000
CY2020Q4 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
19997000
CY2021Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2330000
CY2020Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
734000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11405000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10606000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
477000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
312000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7353000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18921000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55524000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
89671000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39634000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1183000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1557000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7500000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4125000
CY2021Q4 us-gaap Liabilities
Liabilities
117275000
CY2020Q4 us-gaap Liabilities
Liabilities
100840000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31656035
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31262769
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30511226
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28516010
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
601523000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
579755000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-529370000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-385487000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72156000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
194271000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189431000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295111000
CY2021 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
4933000
CY2020 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
2812000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72338000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98148000
CY2021 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
18000
CY2020 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
157000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62742000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27517000
CY2021 us-gaap Operating Expenses
OperatingExpenses
135080000
CY2020 us-gaap Operating Expenses
OperatingExpenses
125665000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-135080000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-125665000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
1091000
CY2021 us-gaap Interest Expense
InterestExpense
6788000
CY2020 us-gaap Interest Expense
InterestExpense
4581000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-95000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2056000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8803000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3403000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-143883000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-129068000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.89
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.88
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37002959
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33228158
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
227955000
CY2020 phat Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity
AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
318000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5840000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-129068000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
194271000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1944000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
903000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16812000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
819000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1290000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-143883000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72156000
CY2021 us-gaap Profit Loss
ProfitLoss
-143883000
CY2020 us-gaap Profit Loss
ProfitLoss
-129068000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
521000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
323000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
16812000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5840000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
990000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3595000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1273000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-95000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-823000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-322000
CY2021 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
82000
CY2020 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
-82000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-605000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7963000
CY2021 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
2766000
CY2020 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
399000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9791000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24009000
CY2021 phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
-18595000
CY2020 phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
19997000
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
165000
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
156000
CY2021 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
98000
CY2020 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
-205000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-43000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
203000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148617000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69688000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
328000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1040000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-328000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1040000
CY2020 phat Proceeds From Underwritten Public Offering Net
ProceedsFromUnderwrittenPublicOfferingNet
88830000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1944000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
629000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
54125000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
96889000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44708000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114459000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104237000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43731000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
287496000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
243765000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183259000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
287496000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
4069000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3464000
CY2021 phat Noncash Issuance Of Common Stock Warrants In Connection With Long Term Debt
NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt
1290000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
145000
CY2021 phat Non Cash Final Interest Payment Fee
NonCashFinalInterestPaymentFee
7500000
CY2020 phat Non Cash Final Interest Payment Fee
NonCashFinalInterestPaymentFee
2063000
CY2021 phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
819000
CY2021 phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
903000
CY2020 phat Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
1396000
CY2020 phat Conversion Of Warrant Liabilities Into Equity
ConversionOfWarrantLiabilitiesIntoEquity
318000
CY2020 phat Unpaid Underwritten Public Offering Costs
UnpaidUnderwrittenPublicOfferingCosts
234000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p>
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021 phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1502000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1317000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
852000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
331000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
986000
CY2021 us-gaap Depreciation
Depreciation
500000
CY2020 us-gaap Depreciation
Depreciation
300000
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020 phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2021Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3165000
CY2020Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4864000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6344000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4587000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1855000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1123000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11405000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10606000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2373000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2373000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1183000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1557000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1670000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2031000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
503000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
516000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
529000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
342000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1890000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
220000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1670000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1183000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M21D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2021Q4 phat Long Term Debt Noncurrent Excluding Unamortized Debt Discount
LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
100990000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11319000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
89671000
CY2021Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
5704000
CY2021Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
5900000
CY2021Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
17308000
CY2021Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
50912000
CY2021Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
66948000
CY2021Q4 phat Long Term Debt And Interest
LongTermDebtAndInterest
146772000
CY2021Q4 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
46772000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2746759
CY2021 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
1601950
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1144809
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14646341
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2728742
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.36
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34432000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1725250
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.14
CY2021 phat Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested
-107583
CY2021 phat Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice
18.07
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
159680
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
32.26
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4186729
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M4D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13973000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1127877
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.75
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M28D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6880000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4186729
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y5M4D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13973000
CY2021 phat Closing Market Price Of Common Stock
ClosingMarketPriceOfCommonStock
19.67
CY2020 phat Closing Market Price Of Common Stock
ClosingMarketPriceOfCommonStock
33.22
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
46600000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M4D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6746
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6507
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0068
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0051
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16812000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5840000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-30216000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-27105000
CY2021 phat Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
1387000
CY2020 phat Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
291000
CY2021 phat Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt
IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
0
CY2020 phat Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt
IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
-20000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2950000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3047000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
31783000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
29949000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-68000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
60936000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33162000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6694000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3744000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13809000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
14929000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3996000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1914000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
85435000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53749000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
85033000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53250000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
402000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
499000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
402000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
499000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
938000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
176000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
64000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
702000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
762000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1704000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
938000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1700000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2021Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
8356
CY2021Q3 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
18394
CY2022Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
16756

Files In Submission

Name View Source Status
0000950170-22-002536-index-headers.html Edgar Link pending
0000950170-22-002536-index.html Edgar Link pending
0000950170-22-002536.txt Edgar Link pending
0000950170-22-002536-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img45497886_0.jpg Edgar Link pending
img45497886_1.jpg Edgar Link pending
img45497886_10.jpg Edgar Link pending
img45497886_11.jpg Edgar Link pending
img45497886_12.jpg Edgar Link pending
img45497886_13.jpg Edgar Link pending
img45497886_14.jpg Edgar Link pending
img45497886_15.jpg Edgar Link pending
img45497886_16.jpg Edgar Link pending
img45497886_17.jpg Edgar Link pending
img45497886_18.jpg Edgar Link pending
img45497886_19.jpg Edgar Link pending
img45497886_2.jpg Edgar Link pending
img45497886_20.jpg Edgar Link pending
img45497886_3.jpg Edgar Link pending
img45497886_4.jpg Edgar Link pending
img45497886_5.jpg Edgar Link pending
img45497886_6.jpg Edgar Link pending
img45497886_7.jpg Edgar Link pending
img45497886_8.jpg Edgar Link pending
img45497886_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
phat-20211231.htm Edgar Link pending
phat-20211231.xsd Edgar Link pending
phat-20211231_cal.xml Edgar Link unprocessable
phat-20211231_def.xml Edgar Link unprocessable
phat-20211231_htm.xml Edgar Link completed
phat-20211231_lab.xml Edgar Link unprocessable
phat-20211231_pre.xml Edgar Link unprocessable
phat-ex10_30.htm Edgar Link pending
phat-ex23_1.htm Edgar Link pending
phat-ex24_1.htm Edgar Link pending
phat-ex31_1.htm Edgar Link pending
phat-ex31_2.htm Edgar Link pending
phat-ex32_1.htm Edgar Link pending
phat-ex32_2.htm Edgar Link pending
phat-ex4_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending